Literature DB >> 21193867

G protein-coupled receptors: novel targets for drug discovery in cancer.

Rosamaria Lappano1, Marcello Maggiolini.   

Abstract

G protein-coupled receptors (GPCRs) belong to a superfamily of cell surface signalling proteins that have a pivotal role in many physiological functions and in multiple diseases, including the development of cancer and cancer metastasis. Current drugs that target GPCRs - many of which have excellent therapeutic benefits - are directed towards only a few GPCR members. Therefore, huge efforts are currently underway to develop new GPCR-based drugs, particularly for cancer. We review recent findings that present unexpected opportunities to interfere with major tumorigenic signals by manipulating GPCR-mediated pathways. We also discuss current data regarding novel GPCR targets that may provide promising opportunities for drug discovery in cancer prevention and treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21193867     DOI： 10.1038/nrd3320

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  218 in total

Review 1.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

Review 2.  From purified GPCRs to drug discovery: the promise of protein-based methodologies.

Authors:  Fatima Alkhalfioui; Thierry Magnin; Renaud Wagner
Journal:  Curr Opin Pharmacol       Date:  2009-05-13       Impact factor: 5.547

3.  GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5.

Authors:  Chang-Wook Lee; Richard Rivera; Shannon Gardell; Adrienne E Dubin; Jerold Chun
Journal:  J Biol Chem       Date:  2006-06-14       Impact factor: 5.157

Review 4.  New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades.

Authors:  K L Pierce; L M Luttrell; R J Lefkowitz
Journal:  Oncogene       Date:  2001-03-26       Impact factor: 9.867

Review 5.  Gastrin-releasing peptide links stressor to cancer progression.

Authors:  Xinqiu Li; Yunfu Lv; Aihua Yuan; Zongfang Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-06       Impact factor: 4.553

6.  Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.

Authors:  Grégoire P Prévost; Marie O Lonchampt; Susan Holbeck; Samir Attoub; Daniel Zaharevitz; Mike Alley; John Wright; Marie C Brezak; Hélène Coulomb; Ann Savola; Marion Huchet; Sophie Chaumeron; Quang-Dé Nguyen; Patricia Forgez; Erik Bruyneel; Mark Bracke; Eric Ferrandis; Pierre Roubert; Danièle Demarquay; Christian Gespach; Philip G Kasprzyk
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.

Authors:  Matthias Lauth; Asa Bergström; Takashi Shimokawa; Rune Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

8.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

9.  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.

Authors:  Honglu Zhang; Xiaoyu Xu; Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; James I Fells; Donna Perygin; Abby L Parrill; Gabor Tigyi; Glenn D Prestwich
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

Review 10.  Role of thrombin in angiogenesis and tumor progression.

Authors:  Nikos E Tsopanoglou; Michael E Maragoudakis
Journal:  Semin Thromb Hemost       Date:  2004-02       Impact factor: 4.180
View more
  291 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.

Authors:  Qiang Wei; Stefano Costanzi; Qiu-Zhen Liu; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2011-05-23       Impact factor: 5.858

3.  Signaling pathways: Purinosomes under GPCR control.

Authors:  Klaus Mohr; Evi Kostenis
Journal:  Nat Chem Biol       Date:  2011-11-15       Impact factor: 15.040

Review 4.  Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets.

Authors:  Xiao-long Tang; Ying Wang; Da-li Li; Jian Luo; Ming-yao Liu
Journal:  Acta Pharmacol Sin       Date:  2012-02-27       Impact factor: 6.150

5.  Imaging of Tissue-Specific and Temporal Activation of GPCR Signaling Using DREADD Knock-In Mice.

Authors:  Dmitry Akhmedov; Nicholas S Kirkby; Jane A Mitchell; Rebecca Berdeaux
Journal:  Methods Mol Biol       Date:  2019

6.  Pendant-bearing glucose-neopentyl glycol (P-GNG) amphiphiles for membrane protein manipulation: Importance of detergent pendant chain for protein stabilization.

Authors:  Hyoung Eun Bae; Cristina Cecchetti; Yang Du; Satoshi Katsube; Jonas S Mortensen; Weijiao Huang; Shahid Rehan; Ho Jin Lee; Claus J Loland; Lan Guan; Brian K Kobilka; Bernadette Byrne; Pil Seok Chae
Journal:  Acta Biomater       Date:  2020-06-06       Impact factor: 8.947

7.  Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors.

Authors:  Xun Shang; Fillipo Marchioni; Chris R Evelyn; Nisha Sipes; Xuan Zhou; William Seibel; Matthew Wortman; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

Authors:  Sandra Claes; Thomas D'huys; Anneleen Van Hout; Dominique Schols; Tom Van Loy
Journal:  J Vis Exp       Date:  2018-02-20       Impact factor: 1.355

9.  Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.

Authors:  Feng-Juan Gao; Jie-Yu Chen; Hong-Yan Wu; Jiong Shi; Ming Chen; Xiang-Shan Fan; Qin Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.

Authors:  Silvana Konermann; Mark D Brigham; Alexandro E Trevino; Julia Joung; Omar O Abudayyeh; Clea Barcena; Patrick D Hsu; Naomi Habib; Jonathan S Gootenberg; Hiroshi Nishimasu; Osamu Nureki; Feng Zhang
Journal:  Nature       Date:  2014-12-10       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.